Drug intelligence / Profile preview

P-TET

Development stage: Preclinical
Lead developer: NanoPharmaceuticals
Modality: Nanoparticles → Drug Delivery Systems

Overview

P-TET is a preclinical-stage nanoparticle drug candidate under development by Nano-Pharmaceuticals for the treatment of inflammatory skin diseases, specifically psoriasis and rosacea. As a nanoparticle formulation, P-TET is designed to target localized inflammation in the skin, though its specific molecular targets and detailed mechanism of action have not been publicly disclosed. The candidate is currently in the initial phases of preclinical planning and development.

Beyond the preview

Go deeper on P-TET.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on P-TET.

Explore the full profile